Aref et al., found that 28/43 (or 65%) of B-ALL cases exhibited CD200, 5/43 (11.6%) expressed CD56, and only two patients (4.7%) expressed both CD200 and CD56. This evidence concerns the gene NCAM1 and precursor B-cell acute lymphoblastic leukemia.